Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy. (12th November 2020) - Haddad, N.; Delyon, J.; Trabelsi Messai, S.; Herms, F.; Leccia, M.T.; Lebbe, C.; Whitney, J.; Bhatia, S.; Basset‐Seguin, N.